Results 241 to 250 of about 4,055,099 (393)

Pharmacokinetics, Safety, and Tolerability of Single‐Dose Dazukibart in Healthy Adults in China and Japan: Results From 2 Randomized, Double‐Blind, Phase 1 Studies

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Dazukibart is a humanized monoclonal antibody selectively targeting interferon‐β. The pharmacokinetics (PK), safety, tolerability, and immunogenicity of dazukibart were evaluated in 2 double‐blind, randomized, placebo‐controlled, single‐dose, Phase 1 studies in healthy adults in China (Study 1: N = 18; dazukibart 900 mg = 15; placebo = 3) and ...
Naihan Chen   +10 more
wiley   +1 more source

ALCOHOL RELATED TRAFFIC SAFETY LEGISLATION

open access: gold, 2002
E. Desapriya   +2 more
openalex   +1 more source

PERSIAN traffic safety and health cohort: a population-based precrash cohort study. [PDF]

open access: yesBMJ Open
Golestani M   +15 more
europepmc   +1 more source

Model‐Informed Drug Development Applications and Opportunities in mRNA‐LNP Therapeutics

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The utilization of lipid nanoparticles (LNP) for encapsulating mRNA has revolutionized the field of therapeutics, enabling the rapid development of COVID‐19 vaccines and cancer vaccines. However, the clinical development of mRNA‐LNP therapeutics faces numerous challenges due to their complex mechanisms of action and limited clinical experience.
Jiawei Zhou   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy